Table 4.

Comparison of drug resistance between 28-day survivors and non-survivors (n,%).

Antibacterial drugs	Survivors (n = 170)	Non-survivors (n = 127)	p
Piperacillin/tazobactam	46 (27) (3 intermediates)	84 (66.1) (2 intermediates)	<0.001
Cefoperazone/sulbactam	81 (47.6) (3 intermediates)	101 (79.5) (2 intermediates)	<0.001
Cefazoline	93 (54.7)	105 (82.6)	<0.001
Ceftriaxone	82 (48.2) (2 intermediates)	102 (80.3)	<0.001
Ceftaxime	64 (37.6) (2 intermediates)	86 (67.7) (1 intermediate)	<0.001
Cefepime	58 (34.1) (1 intermediate)	81 (63.7)	<0.001
Amintronem	70 (41.1)	89 (70) (3 intermediates)	<0.001
Imipenem	43 (25.2) (1 intermediate)	79 (62.2)	<0.001
Ertapenem	42 (24.7) (2 intermediates)	82 (64.5)	<0.001
Tobramycin	50 (29.4) (19 intermediates)	68 (53.5) (17 intermediates)	<0.001
Amikacin	35 (20.5)	63 (49.6) (1 intermediate)	<0.001
Levofloxacin	59 (34.7) (3 intermediates)	83 (65.3) (4 intermediates)	<0.001
Ciprofloxacin	65 (38.2) (3 intermediates)	89 (70) (5 intermediates)	<0.001
Cotrimoxazole	73 (42.9)	72 (56.6)	<0.001
Polymyxin B	0 (1 intermediate)	0 (3 intermediates)
Tigecycline	0 (2 intermediates)	0 (5 intermediates)